Press Releases May 28, 2026 08:00 AM

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

By Marcus Reed AKBA

Akebia Therapeutics announced that its Chief Financial and Business Officer and Chief Commercial Officer will present at the 2026 Jefferies Global Healthcare Conference. The company focuses on biopharmaceutical treatments for kidney disease and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
AKBA

Key Points

  • Akebia Therapeutics will present at a major healthcare investor conference, potentially increasing visibility among investors.
  • Presentation led by senior executives including CFO and Chief Commercial Officer, signaling possible updates on financial and commercial strategies.
  • The event offers a platform to highlight advancements and future plans related to kidney disease treatments.
  • Impacted sectors include biotech, pharmaceuticals, and healthcare investment markets.

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation.

The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. 

Akebia Therapeutics Contact
Mercedes Carrasco
[email protected] 


Risks

  • No new product data or financial guidance provided, which may limit investor enthusiasm.
  • Uncertainty around the company's commercial prospects and pipeline developments until detailed updates are disclosed.
  • Broader biotech sector volatility could affect investor response regardless of the presentation’s content.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026